Omeros (OMER) has set a near term catalyst, with third quarter 2026 results due after the close on November 16, along with a conference call covering recent pipeline developments.
Recent trading has been choppy for Omeros, with the share price down 12.76% over the past month and 5.31% over the past week, yet still up 26.19% over 90 days and supported by a very large 1-year total shareholder return of 151.09%.
Scan how Omeros compares with other potential breakout candidates in the sector by reviewing a curated list of 36 healthcare AI stocks.
Bulls point to Omeros’ steep one year rerating and the gap to analyst targets as evidence the story still has room, while bears focus on volatility and clinical risk. Which side does the current valuation appear to favor?
Most Popular Narrative: 37% Undervalued
Against a last close of $17.30, the analyst consensus Narrative on Simply Wall St points to a fair value of $27.50 for Omeros, implying a sizeable valuation gap that the market has yet to close. That view pulls together detailed assumptions on the pipeline, profitability, and a 7.24% discount rate to frame what the business could be worth.
The expected closing of the Novo Nordisk transaction, with US$240 million upfront and up to US$2.1 billion in total potential consideration plus royalties, would remove near term debt obligations and extend the cash runway. This could ease funding risk and support future revenue and earnings growth from the remaining pipeline.
See why 3 investors see Omeros as 37% undervalued.
Result: Fair Value of $27.50 (UNDERVALUED)
Still, the Omeros narrative leans heavily on Yartemlea approvals and Novo Nordisk cash flows, so any regulatory setback or delay in payments could quickly change sentiment.
Find out about the key risks to this Omeros narrative.
Next Steps
Does the current Omeros story feel more like an opportunity or a hazard to you right now? Act while sentiment is still forming and stress test that view against our breakdown of 4 key rewards and 4 important warning signs.
Looking for more ideas beyond Omeros?
If Omeros has sharpened your interest, do not stop here. Use focused stock lists to pressure test your views and spot opportunities before the crowd does.
- Target resilience first and scan a 30 resilient stocks with low risk scores that filters for companies with sturdier risk profiles than the wider market.
- Hunt for value by reviewing a 35 high quality undervalued stocks that blends quality fundamentals with pricing that models suggest may not fully reflect that strength.
- Prioritise financial strength and run through a list of solid balance sheet and fundamentals (24 results) to focus on businesses supported by cleaner debt levels and healthier cash positions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com